Viatris Q3 revenue and adjusted EPS beat estimates, helped by Aculys Pharma acquisition

Viatris

06/11/2025 12:06

Overview

Viatris Q3 2025 revenue beats analyst expectations, adjusted EPS also exceeds estimates

Company acquires Aculys Pharma, gaining rights to pitolisant and Spydia in Japan

Company returns over $920 mln to shareholders, including $500 mln in share repurchases

Outlook

Viatris raises 2025 revenue guidance to $13.9 bln-$14.3 bln

Company estimates 2025 adjusted EBITDA at $4.0 bln-$4.2 bln

Viatris expects 2025 adjusted EPS of $2.25-$2.35

Result Drivers

ACQUISITION IMPACT - Acquisition of Aculys Pharma expands product rights in Japan, contributing to growth

CAPITAL RETURN - Over $920 mln returned to shareholders, including $500 mln in share repurchases

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$3.76 bln
$3.61 bln (6 Analysts)
Q3 Adjusted EPS
Beat
$0.67
$0.62 (6 Analysts)
Q3 EPS
-$0.11
Q3 NET INCOME
-$128.20 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 5 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Viatris Inc is $12.00, about 10.4% above its November 5 closing price of $10.75

The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago

Press Release: ID:nPn3RG4Qva

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)